FDA has accepted applications for new supplementary drugs from Incyte's Jakafi ® (Ruxolitinib) to treat acute transplant anti-host disease

recently, Incyte(announced that theFDA(Ruxo®litinib) has been accepted for the treatment of the acute graft anti-host disease (GVHD) of corticosteroids under-responsive
and given priority reviews of the new drug(sNDA)RuxolitinibRuxolitinib is a pioneering JAK 1/JAK 2 tyrosine kinase inhibitorFDA approval was obtained in November 2011 for the treatment of patients with moderate or high-risk bone marrow fibrosis (MF), including primary MF, post-true erythin MF, and primary thromeusis Mwas again approved by the FDA in December 2014 to treat patients with real red blood cell hypertrophy (PV) who have insufficient or non-resistant reactions to hydroxyureaIn addition to acute and chronic GVHD, isopreite platelet hyperplasia, thedrug(also developed for the treatment of vitiligo, isotrophic dermatitis and other skin diseases)this sNDA submission is based on data from the REACH1 study, which assessed the effectiveness and safety of patients with acute GVHD who were treated with corticosteroid sylline combination with corticosteroidstheof the ongoingtrial (the results showed that on the 28th day, the overall therapeutic effectiveness was 55% (n-39/71), which was also the main end of the study In addition, the optimal total total efficiency is 73% (n-52/71) the FDA previously gave ruxolitinib a breakthrough treatment for acute GVHD, with the aim of accelerating the development and review of the drug In addition, the FDA has granted ruxolitinib the identification of orphan drugs for the treatment of GVHD